Another study demonstrated that CRC patients with BRAF or KRAS mutated tumors were more likely to have an elevated serum level of carbohydrate antigen (CA19-9) and carcinoma embryonic antigen (CEA) [61]. The gene discussed is KRAS; the disease is colorectal carcinoma.